Search
Thallium Tl-201
go.drugbank.com/drugs/DB15361InvestigationalThallium Tl-201 is under investigation in clinical trial NCT02697760 (The CZT Dynamic Myocardial Perfusion Imaging).
Synonyms: Thallium Tl-201NUC B1000
go.drugbank.com/drugs/DB05242ExperimentalNUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA ...
Caprospinol
go.drugbank.com/drugs/DB05263ExperimentalCaprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
PZ-128
go.drugbank.com/drugs/DB11839InvestigationalPZ-128 has been used in trials studying the prevention and treatment of Heart Diseases, Coronary Disease, Arteriosclerosis, Vascular Diseases, and Myocardial Ischemia, among others.
Cadonilimab
go.drugbank.com/drugs/DB16680InvestigationalCadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).
HKI-357
go.drugbank.com/drugs/DB13002InvestigationalHki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).
Moxetumomab pasudotox
go.drugbank.com/drugs/DB12688ApprovedInvestigationalCD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL2...
PA-1050040
go.drugbank.com/drugs/DB06039ExperimentalPA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Tetracycline
go.drugbank.com/drugs/DB00759ApprovedInvestigationalVet approvedWithdrawnThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: TETRACICLINA CAPSULAS X 250 MG.Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis.
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates